- €445.36m
- €510.81m
- €65.43m
Brief: Genfit SA Says Revenues Total €59.0 Million Including €48.7 Million Milestone In June 2024
Brief: Genfit SA -Genfit Is Eligible To Receive A EUR 48.7 Million Milestone Payment From Ipsen Upon First Commercial Sale Of Iqirvo In U.S.
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug (updated)
US FDA approves Genfit and Ipsen's liver disease drug
Brief: Genfit Q1 Revenue Falls to EUR 1.1 Million
Brief: Genfit Reports Revenues Amounted To EUR 28.6 Mln As Of December 31, 2023
Brief: Genfit Revenues EUR 28.6 Mln As Of Dec. 31, 2023
Brief: Genfit Says Revenues For 2023 Amounted To Eur 28.6 Million Compared To Eur 20.2 Million In 2022
Brief: Genfit Updates 2024 Outlook After Elafibranor Filings In Primary Biliary Cholangitis
Brief: Genfit Announces Publication In The Journal Of Hepatology On NIS2+
Brief: Genfit Says Phase 2 Interim Data Readout From Lead Program Versus-01 In Aclf Targeted For Q2, 2024
Brief: Genfit 9M Revenue Rises To EUR 14.3 Mln
Brief: Genfit Says H1 2023 Resulted In A Net Loss Of EUR 20.9 Million Compared With A Net Profit Of EUR 10.4 Million In H1 2022
Brief: GENFIT Says Data Shows Greater Efficacy Of Its Hepatitis Detection Test In Older Patients
Genfit rises after liver disease treatment meets late-stage study goal
Brief: Ipsen, Genfit Announce Positive Results From Phase III ELATIVE Trial Of Elafibranor
Brief: Seal Rock Therapeutics Announces Out-Licensing Agreement With Genfit For Development Of Injectable Formulation Of Srt-015 For Acute-On-Chronic Liver Disease
Brief: Genfit Says Licensed Exclusive Rights Of ASK1 Inhibitor SRT-015 From Seal Rock Therapeutics
Brief: Genfit Reports First Quarter 2023 Financial Results